Category Archive for: ‘FDA Warning’

Ban Is Advised on 2 Top Pills for Pain Relief

July 1, 2009By GARDINER HARRISNew York Times ADELPHI, Md. — A federal advisory panel voted narrowly on Tuesday to recommend a ban on Percocet and Vicodin, two of the most popular prescription painkillers in the world, because of their effects on the liver. The two drugs combine a narcotic with acetaminophen, the ingredient found in popular over-the-counter products like Tylenol …

Read More

FDA Issues Warning on Osteoporosis Medication

Mireya HernandezFebruary 4, 2009Mireya Hernandez The Food and Drug Administration came out with some important news on bisphosphonates last month. Bisphosphonates are a common treatment and prevention medication for osteoporosis, and are marketed through brands like Boniva, Fosamax, Actonel and Reclast. The report warns physicians of the possibility of bone, joint and/or muscle pain connected to the use of these …

Read More

FDA Warns of Potential of Serious Side Effects with Topical Numbing Agents

By Todd Neale, Staff WriterMedPage Today ROCKVILLE, Md., Jan. 16 — The FDA has issued a second warning about the potential dangers of using topical anesthetics for relieving pain from medical tests and conditions. The latest advisory was prompted by a report last summer on the results of a randomized trial evaluating the use of lidocaine for the pain and …

Read More

M.R.I.’s May Burn Patients Who Wear Drug Patches

March 6, 2009By GARDINER HARRISThe New York Times WASHINGTON — Federal health officials warned Thursday that patients who wear nicotine or other drug patches during M.R.I. scans risk burns, because some patches contain tiny metal elements that can be heated by the device’s huge magnet. “Some, but not all, of these patches contain a little bit of aluminum, just enough …

Read More

FDA Issues Warning On Arthritis Drugs Over Deaths

By Alice TurnerSeptember 7th 2008eFlux Media The U.S. Food and Drug Administration issued a statement which highlights that manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs’ prescribing information and Medication Guides, to better highlight the risk of developing fungal infections. The FDA found that several patients with …

Read More